Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology

Matejka Rebolj*, Elsebeth Lynge, Ditte Ejegod, Sarah Preisler, Carsten Rygaard, Jesper Bonde

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Objective. To compare the clinical characteristics of four human papillomavirus (HPV) assays: hybrid capture 2 (HC2), cobas, CLART, and APTIMA in Danish women with abnormal cytology. Methods. SurePath samples from 367 consecutive women from Copenhagen, with atypical squamous cells of undetermined significance or worse, were tested with the four assays. These women were routinely recommended for repeated testing or were referred for colposcopy. Their worst histological diagnosis in 29 months from baseline was retrieved from the Danish National Pathology Data Bank. Results. Of the 367 women, 16 (4%) had no follow-up, 232 (63%) had < CIN2, 35 (10%) had CIN2, 81 (22%) had CIN3, and 3 (1%) had cervical cancer. The sensitivity for ≥ CIN3 was 95% (95% CI: 88-99) for HC2, 94% (95% CI: 87-98) for cobas, 93% (95% CI: 85-97) for CLART, and 87% (95% CI: 78-93) for APTIMA. In women of age above 30 years, the sensitivities were 98% (95% CI: 87-100), 93% (95% CI: 80-98), 90% (95% CI: 77-97), and 93% (95% CI: 80-98), respectively. One woman with cervical cancer tested negative on CLART and one on cobas; HC2 and APTIMA were positive in all three cancer cases. The specificity for < CIN3 was low for all assays and varied between 22% and 35%. Similar results were seen for ≥ CIN2. Conclusions. Small differences in clinical characteristics were found for the four HPV assays in Danish women with abnormal cytology aged ≥ 30 years. At younger ages, APTIMA was somewhat less sensitive for high-grade CIN than the three HPV DNA assays.

    Sider (fra-til)474-480
    Antal sider7
    TidsskriftGynecologic Oncology
    Udgave nummer3
    StatusUdgivet - 1 dec. 2014


    Udforsk hvilke forskningsemner 'Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology' indeholder.